S&P 500   5,000.83 (-0.21%)
DOW   37,915.40 (+0.37%)
QQQ   420.87 (-0.60%)
AAPL   165.35 (-1.01%)
MSFT   402.51 (-0.44%)
META   491.71 (-2.01%)
GOOGL   154.77 (-0.79%)
AMZN   177.68 (-0.86%)
TSLA   148.64 (-0.86%)
NVDA   838.49 (-0.97%)
AMD   152.15 (-1.89%)
NIO   3.86 (-3.50%)
BABA   68.73 (-0.22%)
T   16.41 (+0.49%)
F   12.16 (+0.83%)
MU   110.00 (-1.72%)
GE   152.44 (-0.33%)
CGC   8.11 (+3.58%)
DIS   112.24 (-0.17%)
AMC   3.04 (+4.11%)
PFE   25.48 (+0.35%)
PYPL   62.12 (+0.03%)
XOM   120.24 (+1.45%)
S&P 500   5,000.83 (-0.21%)
DOW   37,915.40 (+0.37%)
QQQ   420.87 (-0.60%)
AAPL   165.35 (-1.01%)
MSFT   402.51 (-0.44%)
META   491.71 (-2.01%)
GOOGL   154.77 (-0.79%)
AMZN   177.68 (-0.86%)
TSLA   148.64 (-0.86%)
NVDA   838.49 (-0.97%)
AMD   152.15 (-1.89%)
NIO   3.86 (-3.50%)
BABA   68.73 (-0.22%)
T   16.41 (+0.49%)
F   12.16 (+0.83%)
MU   110.00 (-1.72%)
GE   152.44 (-0.33%)
CGC   8.11 (+3.58%)
DIS   112.24 (-0.17%)
AMC   3.04 (+4.11%)
PFE   25.48 (+0.35%)
PYPL   62.12 (+0.03%)
XOM   120.24 (+1.45%)
S&P 500   5,000.83 (-0.21%)
DOW   37,915.40 (+0.37%)
QQQ   420.87 (-0.60%)
AAPL   165.35 (-1.01%)
MSFT   402.51 (-0.44%)
META   491.71 (-2.01%)
GOOGL   154.77 (-0.79%)
AMZN   177.68 (-0.86%)
TSLA   148.64 (-0.86%)
NVDA   838.49 (-0.97%)
AMD   152.15 (-1.89%)
NIO   3.86 (-3.50%)
BABA   68.73 (-0.22%)
T   16.41 (+0.49%)
F   12.16 (+0.83%)
MU   110.00 (-1.72%)
GE   152.44 (-0.33%)
CGC   8.11 (+3.58%)
DIS   112.24 (-0.17%)
AMC   3.04 (+4.11%)
PFE   25.48 (+0.35%)
PYPL   62.12 (+0.03%)
XOM   120.24 (+1.45%)
S&P 500   5,000.83 (-0.21%)
DOW   37,915.40 (+0.37%)
QQQ   420.87 (-0.60%)
AAPL   165.35 (-1.01%)
MSFT   402.51 (-0.44%)
META   491.71 (-2.01%)
GOOGL   154.77 (-0.79%)
AMZN   177.68 (-0.86%)
TSLA   148.64 (-0.86%)
NVDA   838.49 (-0.97%)
AMD   152.15 (-1.89%)
NIO   3.86 (-3.50%)
BABA   68.73 (-0.22%)
T   16.41 (+0.49%)
F   12.16 (+0.83%)
MU   110.00 (-1.72%)
GE   152.44 (-0.33%)
CGC   8.11 (+3.58%)
DIS   112.24 (-0.17%)
AMC   3.04 (+4.11%)
PFE   25.48 (+0.35%)
PYPL   62.12 (+0.03%)
XOM   120.24 (+1.45%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
$5.59
$5.59
$3.11
$5.60
$955.06M1.153.29 million shs6 shs
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$5.25
$6.52
$4.38
$8.45
$401.68M0.15889,563 shs39,042 shs
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
$7.27
-1.2%
$8.90
$3.78
$13.62
$401.45M1.67182,190 shs12,004 shs
Vapotherm, Inc. stock logo
VAPO
Vapotherm
$1.36
$1.23
$0.75
$7.44
$8.45M-1.113,951 shs435 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
0.00%0.00%0.00%0.00%0.00%
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
0.00%-9.01%-21.99%-32.52%-23.69%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
-1.47%+1.38%-21.03%-11.11%+27.56%
Vapotherm, Inc. stock logo
VAPO
Vapotherm
0.00%-6.21%-2.86%+33.01%-68.45%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
3.9962 of 5 stars
2.25.00.04.21.81.71.9
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
N/AN/AN/AN/A
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
2.33
Hold$6.3821.43% Upside
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/A
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/AN/AN/AN/A

Current Analyst Ratings

Latest PLSE, ATRS, VAPO, and OSUR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/4/2024
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetIn-Line ➝ In-Line$7.00 ➝ $6.50
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
$183.98M5.19$0.13 per share43.89$1.03 per share5.43
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$405.47M0.99$1.34 per share3.92$5.86 per share0.90
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
$700K573.50N/AN/A$0.81 per share8.98
Vapotherm, Inc. stock logo
VAPO
Vapotherm
$68.67M0.12N/AN/A($9.01) per share-0.15

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
$46.29M$0.2423.2925.41N/A21.90%7.43%4.92%N/A
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$53.65M$0.727.29N/AN/A13.23%14.50%12.69%5/8/2024 (Estimated)
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
-$42.21M-$0.89N/AN/AN/A-112.74%-61.09%5/9/2024 (Estimated)
Vapotherm, Inc. stock logo
VAPO
Vapotherm
-$58.19M-$9.90N/AN/A-84.74%N/A-65.84%5/1/2024 (Estimated)

Latest PLSE, ATRS, VAPO, and OSUR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/27/2024Q4 2023
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$0.13$0.22+$0.09$0.17$74.13 million$75.88 million    
2/22/2024Q4 2023
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/A-$1.60-$1.60-$1.60N/A$19.73 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
N/AN/AN/AN/AN/A
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
N/AN/AN/AN/AN/A
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/AN/A
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
0.10
3.08
2.87
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
N/A
9.77
8.57
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/A
6.76
6.76
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/A
2.43
1.23

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
50.41%
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
93.50%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
76.95%
Vapotherm, Inc. stock logo
VAPO
Vapotherm
43.08%

Insider Ownership

CompanyInsider Ownership
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
5.90%
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
3.40%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
69.70%
Vapotherm, Inc. stock logo
VAPO
Vapotherm
15.80%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
201170.85 million160.77 millionOptionable
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
63876.51 million73.91 millionOptionable
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
6155.22 million16.73 millionOptionable
Vapotherm, Inc. stock logo
VAPO
Vapotherm
1826.21 million5.22 millionOptionable

PLSE, ATRS, VAPO, and OSUR Headlines

SourceHeadline
Onymos Powers Connected Cloud App for Global Medical Technology Company, VapothermOnymos Powers Connected Cloud App for Global Medical Technology Company, Vapotherm
dbta.com - March 25 at 5:37 PM
Vapotherm to debut home ventilator to improve patient careVapotherm to debut home ventilator to improve patient care
msn.com - March 20 at 7:36 PM
Onymos and Vapotherm Announce Partnership to Create an End-to-End Internet of Medical Things Solution (IoMT)Onymos and Vapotherm Announce Partnership to Create an End-to-End Internet of Medical Things Solution (IoMT)
finance.yahoo.com - March 20 at 7:36 PM
Vapotherm to Unveil Access365 Home Ventilation Solution at MEDTRADEVapotherm to Unveil Access365 Home Ventilation Solution at MEDTRADE
finance.yahoo.com - March 15 at 10:23 AM
Dr. David Yamane was awarded the Star Research Award at the 2024 Critical Care Congress for the presentation of the HYPERACT Study - a randomized controlled trial demonstrating Vapotherms High Velocity Therapy effectively treats moderate-severe acute exacerbations of COPD, while improving patient comfortDr. David Yamane was awarded the Star Research Award at the 2024 Critical Care Congress for the presentation of the HYPERACT Study - a randomized controlled trial demonstrating Vapotherm's High Velocity Therapy effectively treats moderate-severe acute exacerbations of COPD, while improving patient comfort
prnewswire.com - March 6 at 6:45 AM
Vapotherms HVT 2.0 System Overcomes Regulatory Hurdles for Entry into South Americas Largest Health Care MarketVapotherm's HVT 2.0 System Overcomes Regulatory Hurdles for Entry into South America's Largest Health Care Market
prnewswire.com - February 29 at 6:45 AM
Vapotherm, Inc.: Vapotherm Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsVapotherm, Inc.: Vapotherm Reports Fourth Quarter and Fiscal Year 2023 Financial Results
finanznachrichten.de - February 23 at 7:30 AM
Vapotherm: Q4 Earnings SnapshotVapotherm: Q4 Earnings Snapshot
chron.com - February 22 at 9:28 PM
Vapotherm Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsVapotherm Reports Fourth Quarter and Fiscal Year 2023 Financial Results
prnewswire.com - February 22 at 4:10 PM
Innovations Shaping The Future Of Standalone High Flow Oxygen Therapy Devices Market DynamicsInnovations Shaping The Future Of Standalone High Flow Oxygen Therapy Devices Market Dynamics
opprairie.com - February 12 at 10:06 AM
Vapotherm: Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of Listing, Financial Statements And ExhibitsVapotherm: Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of Listing, Financial Statements And Exhibits
cbonds.com - December 17 at 8:45 AM
OTC Markets Group Welcomes Vapotherm, Inc. to OTCQXOTC Markets Group Welcomes Vapotherm, Inc. to OTCQX
financialpost.com - December 15 at 7:08 AM
NYSE to Commence Delisting Proceedings Against Vapotherm, Inc. (VAPO)NYSE to Commence Delisting Proceedings Against Vapotherm, Inc. (VAPO)
finance.yahoo.com - December 14 at 8:20 PM
Vapotherm Shares Suspended on NYSE, Company Previously Announced Voluntary Delisting PlanVapotherm Shares Suspended on NYSE, Company Previously Announced Voluntary Delisting Plan
marketwatch.com - December 14 at 8:20 PM
Vapotherm Shares Decline 22% on Voluntary Delisting Grom NYSEVapotherm Shares Decline 22% on Voluntary Delisting Grom NYSE
marketwatch.com - December 11 at 1:11 PM
Vapotherm slips on announcing voluntary delisting from NYSE to OTCQX MarketplaceVapotherm slips on announcing voluntary delisting from NYSE to OTCQX Marketplace
msn.com - December 11 at 8:11 AM
Vapotherm Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock Application Pending to Transfer Shares to OTCQXVapotherm Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock Application Pending to Transfer Shares to OTCQX
finance.yahoo.com - December 11 at 8:11 AM
Vapotherm Educates over 8,000 Clinicians in Respiratory Care MonthVapotherm Educates over 8,000 Clinicians in Respiratory Care Month
finance.yahoo.com - November 28 at 8:21 PM
Vapotherm, Inc. (NYSE:VAPO) Q3 2023 Earnings Call TranscriptVapotherm, Inc. (NYSE:VAPO) Q3 2023 Earnings Call Transcript
finance.yahoo.com - November 10 at 2:28 PM
Vapotherm GAAP EPS of -$2.38 misses by $0.18, revenue of $15.2M misses by $1.52MVapotherm GAAP EPS of -$2.38 misses by $0.18, revenue of $15.2M misses by $1.52M
msn.com - November 8 at 7:38 PM
Vapotherm Reports Third Quarter 2023 Financial ResultsVapotherm Reports Third Quarter 2023 Financial Results
finance.yahoo.com - November 8 at 7:38 PM
Vapotherm, Inc. (VAPO) stock price, news, quote & history – Yahoo FinanceVapotherm, Inc. (VAPO) stock price, news, quote & history – Yahoo Finance
uk.finance.yahoo.com - November 8 at 9:36 AM
Earnings Outlook For VapothermEarnings Outlook For Vapotherm
benzinga.com - November 7 at 6:13 PM
Vapotherm To Report Third Quarter 2023 Financial ResultsVapotherm To Report Third Quarter 2023 Financial Results
finance.yahoo.com - November 1 at 8:30 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Antares Pharma logo

Antares Pharma

NASDAQ:ATRS
Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey.
OraSure Technologies logo

OraSure Technologies

NASDAQ:OSUR
OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.
Pulse Biosciences logo

Pulse Biosciences

NASDAQ:PLSE
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Vapotherm logo

Vapotherm

NYSE:VAPO
Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers High Velocity Therapy systems, such as HVT 2.0, Precision Flow Hi-VNI, Precision Flow Plus, and Precision Flow Classic which delivers non-invasive ventilatory support to patients by providing heated, humidified, and oxygenated air at a high velocity to treat patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor that provides compressed air necessary to run the precision flow systems in areas of the hospital without access to a wall gas source; aerosol aeroneb adaptor to facilitate delivery of aerosolized solutions; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol solutions for patients; and tracheostomy adaptors that simplifies the connection of the High Velocity Therapy systems to a tracheostomy collar used to wean patients off mechanical ventilation. In addition, the company offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Module, which helps clinicians maintain oxygen levels within a target range. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.